AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...
The medication works by targeting and inhibiting specific signalling pathways that drive the excessive proliferation of cells in the pulmonary blood vessels. This process helps to reduce vascular ...